Advanced Search
MyIDEAS: Login to save this article or follow this journal

The effects of coxib formulary restrictions on analgesic use and cost: Regional evidence from Canada

Contents:

Author Info

  • Marshall, Deborah A.
  • Willison, Donald J.
  • Grootendorst, Paul
  • LeLorier, Jacques
  • Maclure, Malcolm
  • Kulin, Nathalie A.
  • Sheehy, Odile E.
  • Warren, Leanne
  • Sykora, Kathy
  • Rahme, Elham

Abstract

Background Public insurance plans for pharmaceuticals in Canada differ substantially across provinces in the conditions under which pharmaceuticals are reimbursed. Coxibs provide a good example. Québec had no restrictions on reimbursement for these drugs. Ontario required physicians to submit the clinical indications for their use on the prescription. British Columbia required physicians to seek and receive prior authorisation from the drug plan.Objective This study compares the effects of different reimbursement policies on coxib, non-selective non-steroidal anti-inflammatory drugs (nsNSAIDs), and gastro-protective agent (GPA) use and cost.Study design Analysis of retrospective time series analysis of all NSAID and GPA administrative claims data from April 1997 through December 2002.Setting Administrative claims data from April 1997 through December 2002 for each of the publicly funded drug plans in Québec, Ontario, and British Columbia. In addition, we obtained data from BC PharmaNet, which records all dispensed prescriptions in British Columbia.Patients or other participants Senior beneficiaries (>= 65 years).Main outcome measure We compared the projected total NSAID utilisation in the absence of coxib reimbursement restriction with actual utilisation by province and drug category. Projected utilisation was based on ARIMA modelling and reported as the number of defined daily doses (DDDs) per 100 senior (>=65 years) beneficiaries/month.Results In Ontario, under its "limited use" policy, uptake and steady-state use of coxibs was similar to that in Québec, where there were no restrictions. In British Columbia, publicly funded use of coxibs was 6% of that in Ontario and Québec. Despite a shift to private reimbursement, total coxib use in BC was only 50% of use in Ontario and Québec. The use of all NSAIDS (nsNSAIDS plus coxibs) increased for all provincial drug plans except for BC. The increase and overall rate of total NSAID use was greatest in Ontario. Neither Ontario's nor BC's policies had an impact on use of nsNSAIDs or GPAs.Conclusion Only BC's policy effectively limited publicly funded coxib use. However, there was substantial cost-shifting to out-of-pocket and third party insurance plans in BC.

Download Info

If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
File URL: http://www.sciencedirect.com/science/article/B6V8X-4NYJRV0-1/2/04ec72ab347cabcb1ed4cb8622dc2aea
Download Restriction: Full text for ScienceDirect subscribers only

As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.

Bibliographic Info

Article provided by Elsevier in its journal Health Policy.

Volume (Year): 84 (2007)
Issue (Month): 1 (November)
Pages: 1-13

as in new window
Handle: RePEc:eee:hepoli:v:84:y:2007:i:1:p:1-13

Contact details of provider:
Web page: http://www.elsevier.com/locate/healthpol

Related research

Keywords: Non-steroidal anti-inflammatory drugs Coxibs Cox-2 inhibitors Health policy Drug diffusion Administrative restrictions Special authority Limited use policy Analgesics;

References

No references listed on IDEAS
You can help add them by filling out this form.

Citations

Lists

This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

Statistics

Access and download statistics

Corrections

When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:84:y:2007:i:1:p:1-13. See general information about how to correct material in RePEc.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Zhang, Lei) or () The email address of this maintainer does not seem to be valid anymore. Please ask to update the entry or send us the correct address.

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

If references are entirely missing, you can add them using this form.

If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

Please note that corrections may take a couple of weeks to filter through the various RePEc services.